Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib in intermediate risk early breast cancer
NCT03081234Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Invasive Disease-Free Survival at 90 months. Planned start Mar 2018; status: withdrawn.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03081234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081234.